

# Summary of Product Characteristics

## 1 NAME OF THE VETERINARY MEDICINAL PRODUCT

Dolpac Tablets for Medium Dogs

## 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains:

**Active substances:**

Oxantel	200.28 mg (equivalent to 559 mg of oxantel embonate)
Pyrantel	49.94 mg (equivalent to 144 mg of pyrantel embonate)
Praziquantel	50.00 mg

Excipient to one 950 mg divisible tablet

**Excipients:**

For a full list of excipients, see section 6.1.

## 3 PHARMACEUTICAL FORM

Tablet.  
Pale yellow to yellow, oblong tablet with breaking line.

## 4 CLINICAL PARTICULARS

### 4.1 Target Species

Dogs.

### 4.2 Indications for use, specifying the target species

For curative treatment of dogs harbouring mixed parasitic infestations with the following adult stages of nematode and cestode species:

- Nematodes:
- Toxocara canis*,
  - Toxascaris leonina*,
  - Ancylostoma caniinum*
  - Uncinaria stenocephala*,
  - Trichuris vulpis*.
- Cestodes:
- Dipylidium caninum*,
  - Taenia spp.*
  - Echinococcus multilocularis*
  - Echinococcus granulosus*

### 4.3 Contraindications

See section 4.8.

## 4.4 Special warnings for each target species

Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.

Fleas serve as intermediate hosts for one of the common tapeworms – *Dipylidium caninum*. Tapeworm infestation may reoccur unless control of intermediate hosts (fleas) is undertaken.

## 4.5 Special precautions for use

### **i) Special precautions for use in animals:**

#### **Roundworm and Hookworm infection:**

In some animals, *Ancylostoma caninum* and *Toxocara canis* may not be totally eradicated by the treatment, resulting in a continued risk of egg shedding into the environment. Follow-up examinations of the faeces are advisable and according to the results of these examinations, treatment with a nematodicidal product may be carried out if necessary.

The product is not recommended for use in pups younger than two months old or weighing less than 1 kg.

In debilitated or heavily infested animals, the product should be used only according to a benefit/risk assessment by the responsible veterinarian.

Do not use in animals with known hypersensitivity to any of the components of the product.

### **ii) Special precautions to be taken by the person administering the veterinary medicinal product to animals**

Some constituents of this product may cause allergic reactions or skin irritation.

Avoid contact with the skin.

People with known hypersensitivity to any of the ingredients should avoid contact with this product.

Wash hands after use.

In case of accidental ingestion, seek medical advice and show the package leaflet to the physician.

## 4.6 Adverse reactions (frequency and seriousness)

Vomiting and diarrhoea may be observed following the treatment.

Despite not being observed in studies performed with the product, anorexia can occur as it is a common adverse effect of products containing praziquantel.

## 4.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. The use is not recommended during pregnancy and lactation.

## 4.8 Interaction with other medicinal products and other forms of interaction

Do not use simultaneously with levamisole, piperazine or choline esterase inhibitors.

4.9 Amounts to be administered and administration route

The recommended dose rate is 20 mg oxantel / 5 mg pyrantel / 5 mg praziquantel per kg bodyweight, i.e. one tablet per 10 kg bodyweight in a single intake, by oral route.

Administer the required number of tablets, according to bodyweight, orally, in a single administration. Preferably, dogs should be fasted prior to treatment. Food may be given one hour or more after treatment.

<u>Weight of dog:</u>	<u>Number of tablets:</u>
From 3.1 to 5 kg	½
From 5.1 to 10 kg	1
From 10.1 to 20 kg	2
From 20.1 to 30 kg	3

The tablet can be divided into halves.  
Dogs kept together or in kennels should be treated at the same time.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Administration of the product to healthy dogs at 5 times the recommended dosage for 6 consecutive weeks had no adverse consequences.

4.11 Withdrawal Period(s)

Not applicable.

5 PHARMACOLOGICAL or IMMUNOLOGICAL PROPERTIES

Pharmacotherapeutic Group: Praziquantel, combinations

ATC Vet Code: QP52AA51

5.1 Pharmacodynamic properties

The product contains three active ingredients, pyrantel embonate, oxantel embonate and praziquantel. The spectrum of activity of the product is wide, directed towards gastro-intestinal roundworms (ascaris, whipworm and hookworm) and tapeworms.

Pyrantel has a paralysing effect on roundworm muscles, by activating acetylcholine receptors. Its activity is more particularly directed against *Toxocara canis*, *Toxascaris leonina*, *Uncinaria stenocephala* and *Ancylostoma caninum*. Its activity against *Trichuris vulpis* is negligible.

Oxantel is an m-oxyphenolic derivate of pyrantel, that has been developed for its activity against whipworms.

Praziquantel leads to muscular contractions, paralysis and altered parasite tegument integrity. It is active against adults and larval stages of dog tapeworms, *Echinococcus*, *Taenia* and *Dipylidium*.

## 5.2 Pharmacokinetic properties

After oral administration, the absorption of oxantel embonate is negligible. Pyrantel is quickly absorbed but in small quantities ( $T_{\max} = 1.38$  h,  $C_{\max} = 0.048$  µg/ml) and is very quickly eliminated. Praziquantel is quickly absorbed ( $T_{\max} = 1.28$  h,  $C_{\max} = 0.4$  µg/ml) and eliminated (elimination half-life 1.5 h).

## 6 PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

Dextrates  
Povidone K30  
Sodium lauryl sulphate  
Bacon flavour  
Crospovidone  
Sodium stearyl fumarate

### 6.2 Incompatibilities

Not applicable.

### 6.3 Shelf-life

Shelf-life of the veterinary medicinal product as packaged for sale: three years.  
Discard any unused half tablet.

### 6.4 Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

### 6.5 Nature and composition of immediate packaging

Polyamide-aluminium-PVC/aluminium or Polychlorotrifluoroethylene-PVC / aluminium blister strip of 3 tablets  
Cardboard box with 1 strip of 3 tablets  
Cardboard box with 6 strips of 3 tablets  
Cardboard box with 10 strips of 3 tablets  
Cardboard box with 20 strips of 3 tablets  
Cardboard box with 1 strip of 6 tablets  
Cardboard box with 3 strips of 6 tablets  
Cardboard box with 5 strips of 6 tablets  
Cardboard box with 10 strips of 6 tablets  
Not all pack sizes may be marketed

### 6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

**7 MARKETING AUTHORISATION HOLDER**

Vetoquinol UK Limited  
Vetoquinol House  
Great Slade  
Buckingham Industrial Park  
Buckingham  
MK18 1PA  
United Kingdom

**8 MARKETING AUTHORISATION NUMBER(S)**

VPA 10966/032/002

**9 DATE OF THE FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

21st October 2011

**10 DATE OF REVISION OF THE TEXT**